Niagen Bioscience, Inc. — Director's Dealing 2012

Dec 22, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-12-21

Reporting Person: Varvaro Thomas C (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-12-21	Employee Stock Options (right to buy)	$1.545	D	645900	Disposed	2020-05-20	Common Stock (645900)	Direct
2012-12-21	Employee Stock Options (right to buy)	$1.545	D	645900	Disposed	2020-05-20	Common Stock (645900)	Direct
2012-12-21	Employee Stock Options (right to buy)	$1.540	D	95712	Disposed	2021-05-10	Common Stock (95712)	Direct
2012-12-21	Employee Stock Options (right to buy)	$0.945	A	863511	Acquired	2022-09-15	Common Stock (863511)	Direct

Footnotes

F1: These previously awarded options have been terminated in exchange of new award of options under different terms.

F2: Options vest 33 1/3% over three years beginning on May 20, 2011.

F3: Options vest 33 1/3% over three years beginning May 20, 2011; provided further that, these options are only exercisable based on the percentage of warrants exercised as of such vesting date that were issued under that certain Subscription Agreement, dated as of April 22, 2010, between the Issuer and the subscribers named therein. Specifically, if 25% to 49.9% of such warrants have been exercised, then 25% of these options are exercisable; if 50% to 74.9% of such warrants have been exercised, then 50% of these options are exercisable; and if 75% or more of such warrants have been exercised, then 100% of these options are exercisable.

F4: Options vest 25% on May 10, 2012 with the remainder vesting 1/36th per month over three years thereafter.

F5: These new options are awarded by terminating the previously awarded options under different terms.

F6: Options vest 33 1/3% on September 15, 2013 with the remainder vesting 1/24th per month over two years thereafter.

F7: The total includes 1,290,988 options under different terms.